Date: 2014-03-13

Type of information: Licensing agreement

Compound: EB66® cell line for the production of up to three poultry-based veterinary vaccines

Company: Vivalis (now Valneva) (France) Farvet Farmacológicos Veterinarios (Peru)

Therapeutic area: Veterinary medicine

Type agreement:


Action mechanism:



* On June 20, 2012, Vivalis has signed a  non-exclusive commercial license agreement for up to three products with the peruvian veterinary laboratory Farvet FarmacológicosVeterinarios (Farvet) for the development and marketing of animal health vaccines produced in the EB66® cell line. Under this agreement Vivalis will transfer the EB66® cell line and know-how to Farvet  for the commercial development of poultry-based veterinary vaccines. Farvet will have the rights to commercialize one vaccine product with an option to develop two additional products under the same agreement in selected countries in South and Central America.

Financial terms:

Financial terms of the agreement were not disclosed. Upfront and milestone payments along with royalties on net-sales to Vivalis apply to all three candidates.

Latest news:

* On March 13, 2014, Valneva has announced the approval and launch of a second veterinary vaccine produced in the EB66® cell line. The vaccine for the prevention of inclusion body hepatitis virus (IBH) was developed by Lima (Peru) based biopharmaceutical company Farvet, and will also be available for sale in Peru and several other South American countries. Inclusion body hepatitis is an acute disease of young chickens associated with anemia and hemorrhagic disorders. The vaccine is routinely used in many Central and South American countries. Farvet, which licensed the EB66® cell line in June 2012,developed and launched the IBH vaccine into the market in only 20 months. Under the current commercial license, Farvet has the rights to develop two additional vaccines using Valneva’s EB66® cell line. Financial terms of the agreement were not disclosed but do include milestone payments and royalties on net sales of the product.

Is general: Yes